<?xml version="1.0"?>
<Articles JournalTitle="Iranian Journal of Public Health">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Public Health</JournalTitle>
      <Issn>2251-6085</Issn>
      <Volume>44</Volume>
      <Issue>Supple 2</Issue>
      <PubDate PubStatus="epublish">
        <Year>2015</Year>
        <Month>10</Month>
        <Day>21</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Administration of Autologous Mesenchymal Stem Cell Transplantation for Treatment of Type 1 Diabetes Mellitus</title>
    <FirstPage>55</FirstPage>
    <LastPage>68</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Ensieh</FirstName>
        <LastName>NASLI ESFAHANI</LastName>
      </Author>
      <Author>
        <FirstName>Ardeshir</FirstName>
        <LastName>GHAVAMZADEH</LastName>
      </Author>
      <Author>
        <FirstName>Nika</FirstName>
        <LastName>MOJAHEDYAZDI</LastName>
      </Author>
      <Author>
        <FirstName>SeyyedJafar</FirstName>
        <LastName>HASHEMIAN</LastName>
      </Author>
      <Author>
        <FirstName>Kamran</FirstName>
        <LastName>ALIMOGHADAM</LastName>
      </Author>
      <Author>
        <FirstName>Nar&#xAD;jes</FirstName>
        <LastName>AGHEL</LastName>
      </Author>
      <Author>
        <FirstName>Behrouz</FirstName>
        <LastName>NIKBIN</LastName>
      </Author>
      <Author>
        <FirstName>Bagher</FirstName>
        <LastName>LARIJANI</LastName>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2015</Year>
        <Month>10</Month>
        <Day>21</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2015</Year>
        <Month>10</Month>
        <Day>21</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: The aim of the present clinical trial was to investigate the efficacy of autologous bone marrow mesenchymal stem cells (BM-MSCs) in glycemic control of diabetic patients without using any immunosuppressive drugs over a nine-month period.
&#xD;

Method: Twenty-three patients with T1DM, at 5 to 30 years of age and in both sexes, participated in this study. This trial consisted of two phases; in the end of the first phase (three month after the transplantation), if the patient still needed exogenous insulin to control his/her glycemic state, the second phase of study was performed. In both phases, 100 milliliter of mixed mesenchymal stem cells and normal saline containing 2&#xD7;10&#x2076; autologous cells/kg for each patient was delivered to patients through cubital vein. All patients were evaluated at 1, 3, 6 and 9 months after the procedure.
&#xD;

Result: Twenty-one patients underwent a second injection. Nine patients (39%) responded positively and 14 patients (61%) responded negatively based on their HbA1c levels and insulin requirements in both injections. Two patients became insulin-free during two rounds of injections. In responder patients, mean levels of C-peptide and HbA1c as well as prescribed insulin dosage significantly decreased compared to baseline measures (P=0.002, P=0.007 and P&lt;0.001). In the second phase, responder patients did not show significant reduction in C-peptide levels compared to the baseline of the second phase. Mean levels of HbA1c and prescribed insulin dosage significantly decreased in comparison to the beginning of the study (P&lt;0.05).
&#xD;

Conclusion: Transplantation of BM-MSC can be viewed as a promising, simple, safe, and efficient therapeutic modality for T1DM.
&#xD;

&#xA0;
&#xD;

Keywords: Hematopoietic stem cell transplantation, Diabetes mellitus type 1, &#xA0;Autologous
&#xD;

&#xA0;
&#xD;
&#xA0;</abstract>
    <web_url>https://ijph.tums.ac.ir/index.php/ijph/article/view/4916</web_url>
    <pdf_url>https://ijph.tums.ac.ir/index.php/ijph/article/download/4916/4544</pdf_url>
  </Article>
</Articles>
